Breast Cancer Research and Treatment最新文献

{"title":"Effect of chemotherapy timing in triple-negative breast cancer: a real-world evidence study.","authors":"Noiver Graciano, Lucelly López, Carlos A Rodriguez, Katherine Montoya, Diego M González, Luis Rodolfo Gómez, Maycos L Zapata, Javier Cortés","doi":"10.1007/s10549-025-07716-4","DOIUrl":"10.1007/s10549-025-07716-4","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) is an aggressive, heterogeneous malignancy with poor prognosis. The optimal timing of chemotherapy-neoadjuvant (NACT) versus adjuvant (ACT)-remains controversial. This study assessed real-world outcomes in non-metastatic TNBC patients according to chemotherapy timing.</p><p><strong>Methods: </strong>This retrospective study (2008-2023) evaluated the impact of chemotherapy timing on overall survival (OS) and event-free survival (EFS) in a cohort of 711 patients. Propensity score (PS) matching with preoperative variables was used to adjust for baseline imbalances, and Cox regression models were applied to account for treatment-related variables.</p><p><strong>Results: </strong>NACT was administered to 525 patients (73.8%), with a 37.3% pathological complete response (pCR) rate. PS matching yielded 177 patient pairs; tumor stage, age and histologic grade remained unbalanced. In the unadjusted analysis, NACT was associated with worse OS (HR 1.56, 95% CI1.08-2.25, p = 0.018). However, multivariate analysis adjusting for unmatched and postoperative variables showed a potential benefit of NACT for OS (HR 0.53, 95% CI 0.07-4.13, p = 0.545) and EFS (HR 0.94, 95% CI 0.21-4.17, p = 0.932). Tumor stage acted as an effect modifier, and stratified analyses revealed that NACT was superior to ACT in patients with advanced-stage disease who achieved pCR (HR 0.22, 95% CI 0.07-0.7, p < 0.010).</p><p><strong>Conclusions: </strong>In our TNBC cohort, chemotherapy timing significantly influenced OS and EFS, particularly in relation to initial tumor stage and pCR status. NACT was more beneficial than ACT in patients with advanced disease who achieve pCR, underscoring its role in both prognostic stratification and therapeutic decision-making.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"225-236"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression.","authors":"Elisa Perez-Moreno, Victoria Ortega-Hernández, Valentina A Zavala, Jorge Gamboa, Wanda Fernández, Pilar Carvallo","doi":"10.1007/s10549-025-07723-5","DOIUrl":"10.1007/s10549-025-07723-5","url":null,"abstract":"<p><strong>Purpose: </strong>Metastasis, the leading cause of cancer-associated deaths, is promoted by transcription factors SNAIL, SLUG, ZEB1 and TWIST through the activation of epithelial-mesenchymal transition (EMT). MicroRNAs can suppress EMT, emerging as candidate molecular biomarkers and novel therapeutic targets. Herein, we evaluated microRNAs downregulated in breast cancer (BC) tissues expressing EMT transcription factors, to find new potential regulators of EMT.</p><p><strong>Methods: </strong>Candidate microRNAs were selected from microarray data by their inversely correlated expression with SNAIL, SLUG, ZEB1 and TWIST, evaluated in BC tissues through immunohistochemistry. We selected eight microRNAs predicted in silico as probable modulators of SNAIL, SLUG, ZEB1 and TWIST, and validate their interaction through the 3'UTR region in luciferase reporter gene assays. MDA-MB-231 cells were transfected with selected microRNAs to perform migration, invasion and cell proliferation assays, and western blot was used to evaluate protein levels.</p><p><strong>Results: </strong>MiR-30a-5p, miR-1271-5p, miR-196a-5p, miR-202-3p, miR-210-3p, miR-22-3p and miR-331-3p decreased luciferase activity through SNAIL, SLUG, ZEB1 and/or TWIST 3'UTR. These microRNAs, including miR-34b-3p, decreased migration, invasion and cell proliferation in MDA-MB-231 cells. MiR-30a-5p, miR-202-3p and miR-22-3p decreased vimentin expression, whereas miR-196a-5p and miR-22-3p decreased endogenous ZEB1 levels. MiR-196a-5p, miR-202-3p and miR-30a-5p also decreased CCR7 expression, a chemokine receptor involved in lymph node metastasis.</p><p><strong>Conclusion: </strong>microRNAs selected in this work can regulate gene expression trough 3'UTR region of EMT-transcription factors. In BC cells, miR-196a-5p and miR-22-3p decrease ZEB1 levels, being novel modulators of EMT. Also, the eight evaluated microRNAs, reduced the metastatic hallmarks in BC cells.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"277-290"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning prediction of pathological complete response to neoadjuvant chemotherapy with peritumoral breast tumor ultrasound radiomics: compare with intratumoral radiomics and clinicopathologic predictors.","authors":"Jiejie Yao, Wei Zhou, Xiaohong Jia, Ying Zhu, Xiaosong Chen, Weiwei Zhan, Jianqiao Zhou","doi":"10.1007/s10549-025-07727-1","DOIUrl":"10.1007/s10549-025-07727-1","url":null,"abstract":"<p><strong>Purpose: </strong>Noninvasive, accurate and novel approaches to predict patients who will achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) could assist treatment strategies. The aim of this study was to explore the application of machine learning (ML) based peritumoral ultrasound radiomics signature (PURS), compared with intratumoral radiomics (IURS) and clinicopathologic factors, for early prediction of pCR.</p><p><strong>Methods: </strong>We analyzed 358 locally advanced breast cancer patients (250 in the training set and 108 in the test set), who accepted NAC and post NAC surgery at our institution. The clinical and pathological data were analyzed using the independent t test and the Chi-square test to determine the factors associated with pCR. The PURS and IURS of baseline breast tumors were extracted by using 3D-slicer and PyRadiomics software. Five ML classifiers including linear discriminant analysis (LDA), support vector machine (SVM), random forest (RF), logistic regression (LR), and adaptive boosting (AdaBoost) were applied to construct radiomics predictive models. The performance of PURS, IURS models and clinicopathologic predictors were assessed with respect to sensitivity, specificity, accuracy and the areas under the curve (AUCs).</p><p><strong>Results: </strong>Ninety-seven patients achieved pCR. The clinicopathologic predictors obtained an AUC of 0.759. Among PURS models, the RF classifier achieved better efficacy (AUC of 0.889) than LR (0.849), AdaBoost (0.823), SVM (0.746) and LDA (0.732). The RF classifier also obtained a maximum AUC of 0.931 than 0.920 (AdaBoost), 0.875 (LR), 0.825 (SVM), and 0.798 (LDA) in IURS models in the test set. The RF based PURS yielded higher predictive ability (AUC 0.889; 95% CI 0.814, 0.947) than clinicopathologic factors (AUC 0.759; 95% CI 0.657, 0.861; p < 0.05), but lower efficacy compared with IURS (AUC 0.931; 95% CI 0.865, 0.980; p < 0.05).</p><p><strong>Conclusion: </strong>The peritumoral US radiomics, as a novel potential biomarker, can assist clinical therapy decisions.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"325-336"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?","authors":"Clémentine Jankowski, Gilles Houvenaeghel, Celine Renaudeau, Jean Leveque, Frederic Marchal, Amélie Benbara, Emmanuel Barranger, Roman Rouzier, Monique Cohen, Jean-Marc Classe, Sylvain Ladoire, Charles Coutant","doi":"10.1007/s10549-025-07642-5","DOIUrl":"10.1007/s10549-025-07642-5","url":null,"abstract":"<p><strong>Purpose: </strong>Results of MonarchE trial have changed adjuvant therapy for estrogen-receptor-positive (ER+), HER-2-negative breast cancer. Given the importance of the extent of nodal disease in this study, surgical management of the axilla has resurfaced as a question asked at multidisciplinary boards.</p><p><strong>Methods: </strong>Using data from a cohort of Werkoff (JCO, 2009) in which patients underwent both sentinel lymph node(SLN) biopsy and axillary node dissection (ALND), we assessed the proportion of patients in whom the absence of ALND would have led to a lack of awareness of \"high-risk\" status. We evaluated the contribution of the Katz nomogram (that predict pN2/N3 stage) to guide possible indications for complementary ALND.</p><p><strong>Results: </strong>Among the 536 patients, 88 were excluded (ER- and/or isolated cells in SLN). Of patients with 1 or 2 SLN + (n = 352), only 7.9% were pN2/N3. When the ratio (number of SLN + /total number of SLN sampled) was less than 1, only 3.9% were pN2/N3. Patients with 1 or 2 SLN + met the ACOSOG Z0011 criteria so none would benefit from an ALND, but 7.9% of patients at high risk will not receive Abemaciclib. If we use the Katz nomogram (threshold ≤ 5%), this rate decrease at 3.3% but 116 patients will have an ALND with no benefit. With a threshold ≤ 20%, 5% patients at high risk will not receive Abemaciclib but 21 patients will have an ALND with no benefit.</p><p><strong>Conclusion: </strong>The indications for adjuvant Abemaciclib should not lead to surgical escalation in the management of the axilla.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"13-21"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer.","authors":"Avia D Wilkerson, Megan Obi, Corey Gentle, Wei Wei, Camila Ortega, Zahraa Al-Hilli","doi":"10.1007/s10549-025-07703-9","DOIUrl":"10.1007/s10549-025-07703-9","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) screening guidelines for women ages 40-45 have differed across multiple organizations, resulting in variable ages of screening commencement among women in the US. We previously reported that delay in screening beyond age 40 increases risk for first mammogram cancer diagnoses. We hypothesize that first mammogram cancer detection may also diminish recurrence-free and overall survival (RFS, OS).</p><p><strong>Study design: </strong>This retrospective cohort study included 738 women diagnosed with BC from ages 40-45 years and treated within a single hospital system from 2010 to 2019. First mammogram cancers were defined as those with tissue diagnoses established within 3 months of baseline mammogram. RFS after surgery and OS after BC diagnosis were analyzed in patients diagnosed on first versus subsequent mammograms via the Kaplan-Meier method, with p-values generated by log rank tests. Cumulative incidences of local and distant recurrence were also assessed.</p><p><strong>Results: </strong>Of 738 women, 218 had first mammogram cancers while 520 were diagnosed on subsequent mammograms. Median follow-up was 72.2 months (0.5-155.8 months). At 5 and 10 years after diagnosis, OS was significantly worse in patients diagnosed on their first mammogram (0.88 [0.83-0.93] and 0.80 [0.73-0.87]) versus subsequent mammograms (0.95 [0.93-0.97] and 0.90 [0.86-0.93]), p = 0.003. Patients with first mammogram cancers also had inferior 5- and 10-years RFS rates (0.81 [0.71-0.88] and 0.74 [0.65-0.83] vs. 0.88 [0.85-0.92] and 0.77 [0.72-0.83]), p = 0.04.</p><p><strong>Conclusion: </strong>First mammogram cancers were associated with worse survival in our study cohort, reinforcing the importance of consistent guidelines for screening commencement at age 40.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"87-95"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis.","authors":"Chikako Iwai, Atsushi Miyawaki, Takaaki Konishi, Akira Okada, Asahi Fujita, Taisuke Jo, Hideo Yasunaga","doi":"10.1007/s10549-025-07720-8","DOIUrl":"10.1007/s10549-025-07720-8","url":null,"abstract":"<p><strong>Background: </strong>Taxanes are known to be associated with several ocular adverse events; however, large-scale data comparing the risk of ocular adverse events between the two commonly used taxanes, docetaxel (DTX) and paclitaxel (PTX), remain limited. Therefore, we aimed to compare the risks of epiphora, cystoid macular edema, and optic neuropathy between DTX- and PTX-based chemotherapy regimens.</p><p><strong>Methods: </strong>Using a nationwide claims database in Japan, we identified 6038 patients who initiated neoadjuvant or adjuvant taxane-based chemotherapy for breast cancer between April 2014 and November 2022. Data analysis was conducted in 2024. This study was conducted across multiple referral centers and community hospitals in Japan, providing a comprehensive view of taxane-based chemotherapy practices in diverse healthcare settings. Participants included 6038 patients diagnosed with breast cancer who initiated neoadjuvant or adjuvant taxane-based chemotherapy. Eligibility criteria included female patients aged 18 years or older. Participants were selected from a nationwide claims database using a consecutive sampling method. Patients who received DTX-based chemotherapy (DTX group) were compared with those who received PTX-based chemotherapy (PTX group). After adjusting for potential confounders using a propensity score-overlap weighting method, we estimated the incidence of the three ocular adverse events and hazard ratios (HRs) using Cox proportional hazards regression models.</p><p><strong>Results: </strong>Among the 6038 eligible patients, 3829 were in the DTX group and 2209 in the PTX group. The adjusted HR for epiphora in the DTX group was 1.69 [95% confidence interval (CI), 1.17 to 2.45] compared with the PTX group. For cystoid macular edema and optic neuropathy, the adjusted HRs were 0.74 (95% CI, 0.52 to 1.04) and 0.72 (0.47 to 1.11), respectively. The composite incidence of epiphora, cystoid macular edema, and optic neuropathy did not differ significantly between the DTX and PTX groups.</p><p><strong>Conclusion: </strong>Among patients receiving taxane-based chemotherapy for breast cancer, DTX was associated with a higher risk of epiphora compared with PTX. However, the incidence rates of cystoid macular edema and optic neuropathy did not differ significantly between the two groups. These findings offer valuable insights into the ocular adverse event profile of taxane-based chemotherapy in patients with breast cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"173-182"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.","authors":"Christian Maurer, Elisa Agostinetto, Lieveke Ameye, Matteo Lambertini, Samuel Martel, Noam Ponde, Mariana Brandão, Francesca Poggio, Arlindo Ferreira, Rachel Schiff, Carmine De Angelis, Richard D Gelber, Susan Dent, Christoph Thomssen, Martine Piccart, Evandro de Azambuja","doi":"10.1007/s10549-025-07699-2","DOIUrl":"10.1007/s10549-025-07699-2","url":null,"abstract":"<p><strong>Purpose: </strong>There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use and survival outcomes in early HER2-positive breast cancer patients in the phase III APHINITY trial (adjuvant pertuzumab/trastuzumab).</p><p><strong>Methods: </strong>All patients (intent-to-treat population, n = 4804) were included (6.2 years median follow-up database). The primary objective was to investigate the association of statin use on invasive disease-free survival (IDFS), distant relapse-free interval (DRFI), and overall survival (OS). Patients who received statins at baseline, or started statins within 1 year from randomization were considered statin users. Survival curves were estimated using the Kaplan-Meier method. We used a Cox proportional hazards model for multivariate analysis.</p><p><strong>Results: </strong>Overall, 423 (8.8%) patients were classified as statin users. They were older, more often postmenopausal, had a higher body mass index, more often diabetes, hypertension, coronary heart disease and hyperlipidemia, had smaller sized tumors, were treated more often with breast conserving surgery, and less often with anthracycline-containing regimens. Overall, 508 IDFS events (12.8% among statin users and 10.4% among non-statin users) and 272 deaths (8.5% and 5.4%, respectively) occurred. In multivariate analysis, statin use was not associated with IDFS (HR, 1.11; 95% CI, 0.80-1.52), DRFI (HR, 1.21; 95% CI, 0.81-1.81) nor OS (HR, 1.16; 95% CI, 0.78-1.73).</p><p><strong>Conclusion: </strong>In APHINITY, statin use was not associated with improved survival outcomes. These results must be interpreted with caution due to the exploratory nature of the analysis and the associated limitations.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"57-69"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients.","authors":"Shumaila Arif, Noor Muhammad, Boon Hong Ang, Humaira Naeemi, Waqas Sami, Weang Kee Ho, Ute Hamann, Muhammad Usman Rashid","doi":"10.1007/s10549-025-07724-4","DOIUrl":"10.1007/s10549-025-07724-4","url":null,"abstract":"<p><strong>Purpose: </strong>Pathogenic variants (PVs) in BRCA1/2 increase the lifetime risk of breast cancer (BC). Predictive algorithms for BRCA1/2 PVs, primarily developed for Caucasian BC patients, often underestimate carrier probability in Asian populations. The recently developed Asian Risk Calculator (ARiCa) aims to predict BRCA1/2 PV likelihood in Malaysian/Singaporean BC patients. This study investigates the ARiCa's performance in Pakistani female BC patients.</p><p><strong>Methods: </strong>A cohort of 627 high-risk Pakistani female BC patients was evaluated. Using ARiCa, the likelihood of being a BRCA1/2 carrier was estimated based on factors such as age at diagnosis, ethnicity, bilateral BC status, tumor histopathological features, and family history of BC or ovarian cancer. The tool's discriminative ability was evaluated using the area under the curve (AUC).</p><p><strong>Results: </strong>Of the participants, 133 (21.2%) were BRCA1 carriers, 25 (4.0%) were BRCA2 carriers, and 469 (74.8%) were non-carriers. The mean age at BC diagnosis was 34.3 years (range 19-73). Overall, ARiCa showed well calibration for predicting BRCA1/2 (HL 12.11, P = 0.147), BRCA1 (HL 14.17, P = 0.078), and BRCA2 carriers (HL 9.01, P = 0.342). The tool showed acceptable discrimination for BRCA1/2 (AUC 0.77, 95% CI 0.72-0.81) and BRCA1 carriers (AUC 0.80, 95% CI 0.75-0.84), but lower discrimination for BRCA2 carriers (AUC 0.51, 95% CI 0.39-0.64). At a 21% threshold, ARiCa would recommend BRCA1/2 screening for 43% of patients, with sensitivity and specificity at 73% and 68%, respectively.</p><p><strong>Conclusion: </strong>The ARiCa tool demonstrates strong predictive performance for BRCA1/2 carriers, specifically for BRCA1 carriers in Pakistani BC patients, suggesting its potential clinical utility.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"291-298"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating SENOMAC and AMAROS: a call for de-escalation.","authors":"Raquel Diaz, Rebecca Allievi, Piero Fregatti","doi":"10.1007/s10549-025-07743-1","DOIUrl":"10.1007/s10549-025-07743-1","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"415-416"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of loving-kindness meditation intervention vs. music intervention during biopsy on adherence to recommended breast cancer screening.","authors":"Nicole A Arrato, Mary Scott Soo, Anava A Wren, Juliann M Stalls, Dana H Bovbjerg, Francis J Keefe, Rebecca A Shelby","doi":"10.1007/s10549-025-07721-7","DOIUrl":"10.1007/s10549-025-07721-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of providing a loving-kindness meditation (LKM) intervention vs. a music intervention during core-needle breast biopsy (CNBB) on adherence to subsequent, clinically recommended breast cancer screening and surveillance.</p><p><strong>Methods: </strong>Women (N = 120) were randomly assigned to receive LKM, Music, or Usual Care during CNBB. Patients in the LKM or Music groups listened to audio recordings during CNBB and were provided recordings for home use. Utilization of subsequent recommended breast imaging was assessed via health record review for 18 months into the breast cancer surveillance period.</p><p><strong>Results: </strong>The sample was, on average, 53 years old (SD = 12.4), partnered (55%), and employed (56%); 28% Black and 68% White. Adherence to recommended breast imaging post-biopsy was: 69% for Usual Care, 71% for Music, and 90% for LKM. Compared to Usual Care, there was no significant difference in adherence for the Music group (OR = 1.11, 95% CI [0.43, 2.89], p = 0.829), but the LKM group was 3.9 times more likely to be adherent (OR = 3.89, 95% CI [1.13, 13.41], p = 0.032). Comparisons between intervention arms showed adherence for the LKM group was 3.5 times higher than the Music group (OR = 3.50, 95% CI [1.02, 12.00], p = 0.046). Patterns of adherence were similar across women with an abnormal biopsy result and those with a benign result.</p><p><strong>Conclusion: </strong>A LKM intervention initiated during CNBB can have significant, positive impacts on women's adherence to subsequent recommended breast imaging. Providing patients with LKM during CNBB is an easily disseminated approach that could improve adherence to breast cancer screening and surveillance after CNBB.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"261-268"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}